Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer (IV REXBC 02)

This study has been terminated.
(company focus on other projects)
Sponsor:
Information provided by:
Neovii Biotech
ClinicalTrials.gov Identifier:
NCT00351858
First received: July 12, 2006
Last updated: May 18, 2009
Last verified: May 2009
  Purpose

The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer


Condition Intervention Phase
Breast Neoplasms
Breast Cancer
Drug: ertumaxomab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of the Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab for Hormone Therapy Refractory Patients With Her-2/Neu 1+ or 2+ Expressing Advanced or Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Neovii Biotech:

Primary Outcome Measures:
  • To demonstrate clinical efficacy of the investigational trifunctional antibody ertumaxomab for the treatment of hormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV) which are known to express Her-2/neu (1+ or 2+)

Secondary Outcome Measures:
  • Time to progression
  • Duration of response
  • Time to response
  • Clinical benefit of ertumaxomab (defined as the rate of confirmed complete remission, partial remission and stable disease)
  • Tumor marker levels (CA 15-3 and CEA)

Estimated Enrollment: 40
Study Start Date: July 2006
Study Completion Date: February 2009
Detailed Description:

A multi-centre, phase II study of ertumaxomab in metastatic breast cancer patients who became progressive after hormonal therapy. Each eligible patient will receive three ascending doses of ertumaxomab, administered intravenously. Ertumaxomab will be administered as a 3-hour constant rate infusion with a dosing interval of 7 days. Each patient will participate in this study for up to 7 months (includes the up to 21 days screening period, 14 days treatment period, and up to 180 days/6 months follow-up), with 3-monthly post-study follow-up until the patient becomes progressive.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female gender, and if of child-bearing potential must have negative pregnancy test result within 2 days before enrolment and must agree to practice effective birth control during the study.
  • Aged 18 years and older.
  • Histologically or cytologically confirmed invasive breast cancer with stage IIIb or IV disease with documented progression.
  • Measurable disease according to RECIST.
  • Histologically documented advanced primary breast cancer or biopsy of metastatic site demonstrating HER-2/neu expression (HER-2/neu 1+ or 2+, determined by immunohistochemistry [IHC]). HER-2/neu 2+ patients must have a negative Fluorescence In Situ Hybridization [FISH] test result.
  • Hormone receptor status Estrogen Receptors (ERs) positive and/or Progesterone Receptors (PRs) positive.
  • No prior treatment with mouse or rat antibodies.
  • Life expectancy of at least six months (if the life expectancy of a patient is unspecified she will be allowed to enter the study).
  • An Eastern Cooperative Oncology Group (ECOG) performance score of £ 1.
  • Patients must have had disease progression after hormonal therapy including at least one aromatase inhibitor.
  • Adequate hematological, liver and kidney function:

    • Thrombocytes ³ 100000 / mm³ (= 100 x 109 /l)
    • Hemoglobin ³ 10 g/dl
    • Neutrophil count ³ 1500/mm³ (= 1.5 x 109 /l)
    • WBC ³ 3 X 109 /l
    • Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) ≤ 2.5 x upper limit of normal (ULN)
    • Serum bilirubin ≤ 2 x ULN
    • Creatinine ≤ 1.5 x ULN or clearance ³ 60 ml/min
  • No life-threatening visceral disease.
  • No known brain or central nervous system metastases.
  • No symptomatic pleural effusions.
  • No symptomatic pericardial effusions.
  • No subjects whose only site of metastatic involvement is bone metastases with the exception of those with a measurable soft tissue component of the bone lesion seen with imaging that does not require palliative radiation intervention and/or the patient has a lytic bone lesion ³ 1 cm measured with radiography that can be followed for evidence of re-calcification.
  • No history of relevant cardiovascular disease:

    • LVEF within the institutional ranges of normal as measured by echocardiogram or MUGA scan
    • No prior uncontrolled or symptomatic congestive heart failure NYHA ³ 2
    • No myocardial infarction within the past two years
    • No uncontrolled or symptomatic cardiac arrhythmias
  • No severe dyspnea.
  • No pulmonary dysfunction or need for continuous supportive oxygen inhalation.
  • No other concurrent uncontrolled co-morbid illness.
  • No other concurrent malignancy, except treated basal cell or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix.
  • Patients with documented autoimmune diseases (such as lupus) are excluded from participation in the study unless a waiver is granted by the responsible medical monitor.
  • Patients with a human immunodeficiency virus, hepatitis B or hepatitis C positive status are excluded from participation in the study.
  • No prior or concurrent chemotherapy regimen for advanced or metastatic disease.
  • Prior neo-adjuvant or adjuvant chemotherapy is allowed provided it was stopped at least six months before study entry.
  • No concurrent hormone therapy (hormone therapy must be stopped at the screening visit).
  • At least 4 weeks since prior radiotherapy.
  • No concurrent immune therapy.
  • No concurrent corticosteroid therapy.
  • No regularly used medication for a health condition or comorbidity that might result in undue risk to the patient.
  • No prior investigational treatment for advanced or metastatic disease.
  • Able and willing to comply fully with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00351858

Locations
Belgium
Jules Bordet Institute, Free University of Brussels
Brussels, Belgium, 1000
Sponsors and Collaborators
Neovii Biotech
Investigators
Principal Investigator: Fatima Cardoso, MD Brussels
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00351858     History of Changes
Other Study ID Numbers: FBT-IVREXBC 02, EudraT number: 2005-004294-21
Study First Received: July 12, 2006
Last Updated: May 18, 2009
Health Authority: Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
Spain: Spanish Agency of Medicines
Russia: Pharmacological Committee, Ministry of Health
Italy: Ethics Committee

Keywords provided by Neovii Biotech:
Breast Cancer
investigational drug
drug therapy
Antineoplastic Protocols
Immunotherapy
Metastatic breast cancer
Advanced breast cancer
Stage III to IV breast cancer
Hormonal therapy refractory
Failure of hormonal therapy
Her-2/neu expressing breast cancer
low to moderate Her-2/neu expression

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on July 26, 2014